Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03070392
Title Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Immunocore Ltd
Indications

uveal melanoma

Therapies

Dacarbazine

Ipilimumab

Pembrolizumab

Tebentafusp

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.